Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: Clin Cancer Res. 2014 Mar 14;20(10):2740–2750. doi: 10.1158/1078-0432.CCR-13-2507

Figure 1. Expression of PDGFRa and anti-phosphorylation effect of its blockade in cancer cells.

Figure 1

A, Western blot analysis of PDGFRa expression in uterine and ovarian cancer cell lines. B, In vitro effect of 3G3 on PDGFRa, pPDGFRa, and its downstream targets. Cells (Hec-1A) were treated with 3G3 or nonspecific human immunoglobulin G (HmIgG) for 24 hours and then stimulated with 1 nM PDGF-AA for 10 minutes. Cell lysates were analyzed by Western blot analysis with antibodies against PDGFRa, pPDGFRa, p 44/42 MAPK, MAPK, pAKT, and AKT. C, Western blot analysis of expression of PDGFRa downstream targets in RL95-2 cells. RL95-2 cells were treated with 3G3 or PDGF-AA as mentioned above. Loading of an equal amount of sample per gel lane was confirmed by b-actin expression.